A Phase 1 interventional study of Lutikizumab Dose A and Lutikizumab Dose B in Healthy Volunteers, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female healthy volunteers aged between 18 and 60 years.
-- Part 2 only: Participant must be first-generation Han Chinese of full Chinese parentage residing outside of China. Participant must maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of Lutikizumab Dose A.
Drug: Lutikizumab Dose A
Participants will receive a single dose of Lutikizumab Dose B.
Drug: Lutikizumab Dose B
Han Chinese participants will receive a single dose of Lutikizumab.
Drug: Lutikizumab Dose A
Injection; subcutaneous (SC)
Injection; subcutaneous (SC)
Maximum Observed Serum Concentration (Cmax) of Lutikizumab
Cmax of lutikizumab will be assessed.
Time frame: Up to Day 8
Time to Cmax (Tmax) of Lutikizumab
Tmax of lutikizumab will be assessed.
Time frame: Up to Day 8
Apparent Terminal Phase Elimination Rate Constant (β) of Lutikizumab
Apparent terminal phase elimination rate constant (β) of lutikizumab will be assessed.
Time frame: Up to Day 8
Terminal Phase Elimination Half-life (t1/2) of Lutikizumab
Terminal phase elimination half-life (t1/2) of lutikizumab will be assessed.
Time frame: Up to Day 8
Area under the Serum Concentration-time Curve (AUC) from Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of Lutikizumab
AUC0-t of lutikizumab will be assessed.
Time frame: Up to Day 8
AUC from Time 0 to Infinity (AUC0-inf) of Lutikizumab
AUC0-inf of lutikizumab will be assessed.
Time frame: Up to Day 8
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Baseline to Day 71
Plan to share: No
Ran from Sep 2023 to primary completion in Feb 2024, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.